---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038061"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:34:42.655211+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Geron submits NDA for imetelstat in lower risk MDS; Q2 cash $400.2M

## Summary
- Submitted first NDA for a telomerase inhibitor (imetelstat) to FDA for lower risk MDS in June 2023.
- Cash, equivalents and securities of $400.2M as of June 30; expects to fund operations through end of 2025.
- Reaffirmed FY2023 GAAP total expense guidance of $210M–$220M; non-GAAP $200M–$210M.
- IMpactMF Phase 3 trial in myelofibrosis enrolled >40%; interim analysis expected H1 2025.
- Appointed Scott Samuels as EVP, Chief Legal Officer and Corporate Secretary effective August 1, 2023.

## SEC filing metadata
- accession: 0000950170-23-038061
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/0000950170-23-038061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/gern-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038061
- JSON: https://secwatch.observer/filing/0000950170-23-038061.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038061.txt

## Key facts
- Earnings Releases
  GERON CORP reported the three and six months ended June 30, 2023 results: revenue $29,000 and $50,000, respectively.
  - Period: the three and six months ended June 30, 2023
  - Revenue: $29,000 and $50,000, respectively
  - Result: reported results
  source text: to fund its projected operating requirements through the end of 2025. Second Quarter 2023 Financial Results Revenues for the three and six months ended June 30, 2023, were $29,000 and $50,000, respectively, compared to $73,000 and $196,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of cell-based
  evidence_url: https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/0000950170-23-038061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.